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Abstract  
The coxsackievirus and adenovirus receptor (CAR) is a cell contact protein with an important role in virus 
uptake. Its extracellular immunoglobulin domains mediate the binding to coxsackie and adenoviruses as 
well as homophilic and heterophilic interactions between cells. The cytoplasmic tail links CAR to the 
cytoskeleton and intracellular signaling cascades. In the heart, CAR is crucial for embryonic development, 
electrophysiology, and coxsackievirus B infection. Non-cardiac functions are less well understood, in part 
due to the lack of suitable animal models. Here we generated a transgenic mouse that rescued the 
otherwise embryonic lethal CAR-knockout (KO) phenotype by expressing chicken CAR exclusively in 
the heart. Using this rescue model we addressed interspecies differences in coxsackievirus uptake and 
non-cardiac functions of CAR. Survival of the non-cardiac CAR KO mouse (ncKO) indicates an essential 
role for CAR in the developing heart, but not in other tissues. In adult animals cardiac activity was normal, 
suggesting that chicken CAR can replace the physiological functions of mouse CAR in the cardiomyocyte. 
However, chicken CAR did not mediate virus entry in vivo so that hearts expressing chicken- instead of 
mouse CAR were protected from infection and myocarditis. Comparison of sequence homology and 
modeling of the D1 domain indicate differences between mammalian and chicken CAR that relate to the 
sites important for virus binding but not those involved in homodimerization. Thus, CAR-directed anti- 
coxsackieviral therapy with only minor adverse effects in non-cardiac tissue could be further improved by 
selectively targeting the virus-host interaction while maintaining cardiac function. 
 
Importance 
 
Coxsackievirus B3 (CVB3) is one of the most common human pathogens causing myocarditis. Its receptor 
CAR does not only mediate virus uptake but also relates to cytoskeletal organization and intracellular 
signaling. Animals without CAR die prenatally with major cardiac malformations. In the adult heart CAR 
is important for virus entry and electrical conduction, but its non-muscle functions are largely unknown. 
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Here we show that chicken CAR expression exclusively in the heart can rescue the otherwise embryonic 
lethal CAR knockout phenotype but does not support CVB3 infection of adult cardiomyocytes. Our 
findings have implication for the evolution of virus/host versus physiological interactions involving CAR 
and could help to improve future coxsackievirus directed therapies inhibiting virus replication while 
maintaining CAR’s cellular functions. 
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Introduction 
 
Coxsackieviruses belong to the Enterovirus genus in the family of Picornaviridae and are important 
human pathogens, that cause a plethora of infectious diseases such as myocarditis, meningitis, and 
pancreatitis (1). They are one of the most common causes of myocarditis with up to 33% of patients 
positive for coxsackievirus type B (CVB) (2). The classification of coxsackieviruses is based on the 
systemic versus localized pathology in the mouse, which is the experimental model of choice to study the 
CVB3 serotype (3, 4). In addition to mouse and human other species are also infected by CVB3, which 
has been reported in diverse primate species with myocarditis (5–7). Infections with other CVB viruses 
have been reported in primates and dogs (8, 9). Infections of the pig have been attributed to the swine 
vesicular disease (SVD) virus - an adaption of the human CVB5 to the swine (10). 
The coxsackievirus and adenovirus receptor (CAR) has been identified in 1997 (11, 12) and binds group B 
coxsackieviruses, adenoviruses of the subgenus A and C to F, as well as the SVD virus (12–14). CAR is 
crucial for CVB3 uptake as documented by protection from infection of heart or pancreas in the respective 
tissue specific knockouts (3, 4). Virus attachment is mediated by binding of CAR’s N-terminal 
Immunoglobulin (Ig) domain to the canyon of the virus where the viral capsid proteins VP1-3 interact 
with CAR (15). This interaction is conserved in the family of Picornaviridae (16–18). CVB3 viruses use 
the co-receptor “decay accelerating factor” (DAF) for cell attachment (19), which binds adjacent to the 
CAR interaction sites on the virus surface (20). DAF alone is not sufficient for virus infection (21). It has 
been proposed to facilitate the presentation of virions to CAR and contribute to systemic infections 
helping the virus cross epithelial cell barriers (22). 
CAR is a type I transmembrane protein localized in the tight junctions of epithelial cells and in the 
intercalated discs between cardiomyocytes (23, 24). It consists of an N-terminal signal peptide, two 
extracellular Ig-domains, a transmembrane domain and an intracellular tail. Because of its two 
extracellular Ig-like domains CAR belongs to the immunoglobulin superfamily (IgSF) (11). The N-
terminal Ig-domain is important for virus binding, but also for homophilic interactions or interaction with 
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other IgSF proteins (15, 25–27). The cytoplasmic tail contains a PDZ-binding motif (28) that links to the 
cytoskeleton and intracellular signaling cascades (24, 29, 30). 
To analyze the role of CAR in vivo several knockout (KO) animals have been generated (31). 
Conventional CAR KO animals die between embryonic day E11.5 and E13.5 (32–35). The embryos suffer 
from defects in cardiac development, hemorrhage, and edema. Their myofilaments are disorganized and 
less compact than wildtype controls. To circumvent the embryonic lethal phenotype and analyze the 
function of CAR in the adult heart several conditional KO animals have been generated (33, 35, 36). The 
adult KOs revealed a role for CAR in the electrical signal propagation between atria and ventricle (35–37). 
Together this indicates an essential function of CAR in both the embryonic and adult heart. Deletion of 
CAR in non-cardiac tissues did not result in severe phenotypes (3, 37). 
To analyze possible non-cardiac functions of CAR and its role in mediating and sustaining coxsackievirus 
infections we generated a novel animal model that expresses CAR exclusively in cardiomyocytes, but not 
in other cells. With Gallus gallus CAR (chCAR) under control of the heart-specific MLC-2 promoter we 
were able to rescue the embryonic lethal phenotype of the conventional CAR KO. CVB3 infection studies 
of the non-cardiac CAR KO mouse demonstrate the protection from pathology throughout the body, 
including the heart where mouse CAR (mCAR) is replaced with chCAR. Sequence alignment and 
modeling of the protein structure indicated crucial differences in CAR–CVB3 interaction between species. 
The respective aminoacids were less well conserved compared to the amino acids involved in 
homodimerization and cluster differentially within the Ig-domain. 
 
Materials and Methods 
Animal procedures 
All experiments involving animals were carried out following the Guide for the Care and Use of 
Laboratory Animals of the German animal welfare act and protocols were approved by the Committee on 
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the Ethics of Animal Experiments of Berlin State authorities and the regional board of Tübingen. 
Generation of the animal model is described in the supplementary material and methods. 
In brief, we generated a transgenic mouse that expresses the full length CAR protein from Gallus gallus 
including all annotated exons (chCAR) under control of the heart specific MLC-2 promoter, in addition to 
the wildtype mouse CAR. Animals with high expression levels of chCAR as determined by TaqMan 
analysis died early postnatally, while lower levels were compatible with life. These animals were mated 
with heterozygous CAR knockout mice (38) for two generations to obtain rescue animals, which are 
homozygous deficient for mouse CAR and only express chicken CAR in the cardiac ventricle. The colony 
was maintained by breeding animals with and without the transgene to ensure heterozygosity for the 
transgene and to reduce potential side effects from integration of the transgene. 
For echocardiography or ECG analysis, mice were anesthetized with 1.5% Isoflorane. For 
Echocardiography, M and B mode were measured with the Vevo 2100 system (visual sonics) and the 
MS400 transducer. Data acquisition and analysis with the Vevo 2100 Software, including the trace EF [%] 
has been described previously (39). ECG standard intervals were measured in six-limb leads. The ECG 
was recorded with the PL3508 PowerLab 8/35 (AD instruments). Data analysis was performed with the 
LabChart 7.3 software (AD Instruments). For body composition analysis by MR technology we used the 
LF90II body composition analyzer (Bruker). Evans Blue (EB) extravasation assay was performed by 
injecting 4 ml/kg BW of 2% (w/v) EB dye solution intravenously. 2 h later the animals were sacrificed. 
The brains and kidneys were dissected and photographed. 10 mg sections of the organs were then 
homogenized in PBS and mixed with same volumes of 60% trichloroacetic acid and centrifuged (10000 
rpm, 20 min). Absorbance of the supernatants was measured at 620 nm. 
Electron microscopy 
Mice were killed by cervical dislocation and perfused with 4% PFA in phosphate-buffer. Left ventricular 
tissue was post-fixed with 2.5% glutaraldehyde in phosphate-buffer overnight. Tissues were washed with 
cacodylate-buffer, treated with 1% osmiumtetroxide pH 2.5 for 2 h, and dehydrated in a graded ethanol 
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series. Tissues were embedded in Epon, cut in 70 nm sections and contrasted with uranyl- and lead-citrate. 
Pictures were taken with a Zeiss 910 electron-microscope and a CCD camera (Proscan). 
Virus inoculation 
The CVB3 Nancy strain (40) was grown and propagated in Vero cells. Stock virus was prepared by 3× 
freezing and thawing and purified by sucrose gradient centrifugation as described previously (41). The 
same stock was used to infect mice by intraperitoneal injection with 1×105 plaque-forming units (pfu) or 
intravenously with 1x106 pfu of purified CVB3. Animals were analyzed 4 or 10 days after injection (dpi) 
with virus or vehicle. 
Cell culture 
Cells were cultured in DMEM (Lonza) supplemented with 10% FCS, 100 U/ml penicillin and 100 µg/ml 
streptomycin and incubated at 37 °C with 5% CO2. 
Transfection was performed using Lipofectamine 2000 (Invitrogen) following manufacturer’s instructions. 
For one cavity of a 6-well plate 2.6 µg plasmid DNA were used. Protein expression was analyzed 48 h 
after transfection. 
Transfected CHO cells were infected with CVB3 at a multiplicity of infection (MOI) 0.1 for 30 min at 37 
°C. Subsequently, cells were washed twice with PBS. For RNA preparation, cells were lysed 4 h post 
infection with 1 ml Trizol. For plaque assay cells with supernatant were harvested 24 h post infection and 
lysed by three freeze and thaw cycles. 
Plaque assay 
Plaque assays were carried out as described previously (42). Briefly, HeLa cells were cultured in six-well 
culture plates as confluent monolayers at a density of 1 × 106 cells/well. After 24 h, medium was removed 
and cells were overlaid with 1 ml of diluted supernatant harvested from infected CHO cells and then 
incubated at 37°C for 30 min. After removal of the supernatant, cells were overlaid with 2 ml of agar 
containing Eagle's minimal essential medium (MEM). Three days later, the cells were stained with 
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0.025% neutral red in PBS. Virus titers were determined by counting plaques 3 h after staining. Data 
shown represent the results of two independent plaque assays, each performed in duplicate. 
 
Immunofluorescence analysis 
H9C2 cells transfected with the chCAR expression construct were fixed with 4% PFA in PBS and stained 
following the published protocol (43). Primary antibody was a rabbit anti chCAR antibody targeting the 
extracellular domain of chCAR (a generous gift from Fritz Rathjen (26)). As secondary antibody we used 
an anti-rabbit IgG Cy3 conjugated antibody raised in goat (Invitrogen). Image acquisition was performed 
on a Leica SPE microscope and Image analysis was done in ImageJ (44). 
Tissue preparation 
Samples of tissues were either quick frozen in liquid nitrogen for the subsequent preparation of RNA or 
fixed for 12 h in phosphate-buffered (pH 7.2) 4% paraformaldehyde and embedded in paraffin for 
histology, immunohistology, and in situ hybridization. 
Western blot 
Protein preparation, SDS PAGE, and Western blot have been previously described (44). Primary 
antibodies used against chCAR (a generous gift from Fritz Rathjen, 1:500), GAPDH (mouse monoclonal; 
Calbiochem 1:5000), and secondary antibody conjugated with horse radish peroxidase (HRP, GE 
Healthcare Life Sciences 1:5000) were used according to the manufacturer’ s instructions. 
Histopathology 
Histological analysis was performed on deparaffinized 5-μm-thick tissue sections that were stained with 
Massons Trichrome or hematoxylin and eosin (H&E) to assess cellular injury and inflammation (45). 
Immunohistochemistry using the CVB3-specific VP1 antibody (1:400) provided by Mediagnost 
(Reutlingen, Germany) was used to follow CVB3 replication. Subsequently, the sections were processed 
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with the MaxHomo Mouse on Mouse Polymer HRP Detection Kit (MaxVision, Washington, USA) 
followed by HistoGreen substrate (Linaris, Dossenheim, Germany). The tissue sections were 
counterstained with hematoxylin. We evaluated cellular damage comprising cell necrosis, inflammation, 
and scarring as published previously (46) with the following grading system: Score: 0, no cellular damage 
and/or inflammatory infiltrates; 1, small foci of tissue damage and/or inflammatory cells; 2, larger foci of 
damage and/or >100 inflammatory cells; 3, larger foci with an area ≤10% of cross-section involved; 4, 
>10-30% of a cross-section involved; 5, up to 100% of a cross-section involved using a Zeiss Axioskope 
40 microscope.  
CVB3 RNA in situ hybridization  
For localization and quantification of CVB3 RNA in paraffinated tissue sections we used radioactive in 
situ hybridization. At the indicated time points, tissue samples were fixed in 4% paraformaldehyde / 0.1 
mol/l sodium phosphate buffer (pH 7.2) and embedded in paraffin for detection of viral RNA with a 35S-
labeled enterovirus-specific RNA probe as previously described (41, 45). For quantification of CVB3 
RNA in high power fields (×200) we used the following scoring system: 0, no positive cells; 1, a few 
small foci with positive cells; 2, several foci with >100 positive cells; 3, ≤10% of the tissue contains 
positive cells; 4, 10-30% of the tissue contains positive cells; 5, up to 100% of the tissue contains positive 
cells. The same score was used for detection of VP1 positive cells, also reflecting virus replication at the 
cellular level using a Zeiss Axioskope 40 microscope. 
Expression analysis 
RNA from the indicated tissues was amplified with specific TaqMan probes (sequence available on 
request). The gene expression assays for RANTES and Interferon (IFN) beta 1 as well as the 18s RNA as 
housekeeping gene were purchased from Applied Biosystems (Foster City, California). Data acquisition 
and analysis have been previously described (47). 
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Multiplex bead immunoassay 
To measure the serum concentration of RANTES we used the BioPlex Pro mouse cytokine assay (Biorad) 
following the manufacturer’s instructions. The fluorescence signal was detected using the Luminex 200 
system (Millipore). Concentration was determined using a standard curve. All samples were run in 
triplicates. 
Coxsackievirus B3 IgG serum ELISA 
To determine the concentration of CVB3 specific Antibodies the SERION ELISA classic Coxsackievirus 
IgG Kit (Virion Serion) was used following the manufacturer’s instructions. Serum samples were initially 
diluted 1:200. The secondary antibody was replaced by an alkaline phosphatase coupled anti mouse IgG 
antibody (Invitrogen). The signal at 450nm was measured with the F200 Pro (TECAN). All Samples were 
run in triplicates. 
Statistical analysis 
For statistical analysis, GraphPad Prism software 5.0 (San Diego, California) was used. Results are 
expressed as mean ± SEM. To compare two groups student T-test was performed. More than 2 groups 
were analyzed by one way anova. Asterisks indicate statistically significant differences (*, P<0.05; **, 
P<0.01; ***, P<0.001). 
 
Homology modeling of Gallus gallus CAR D1 domain  
The three-dimensional structure of the CAR D1 domain aminoacids 19-144 (UniprotKB accession number 
P78310) from Homo sapiens (PDB ID: 1RSF chain A) was used as template for homology modeling. The 
homology modeling of the Gallus gallus CXADR D1 domain aminoacids 20-139 (UniprotKB accession 
number F1NSL7) was performed using the ESyPred3D homology modeling program (48). The resulting 
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three-dimensional structure was analyzed and compared using the Discovery Studio Visualizer 3.1 
(http://accelrys.com). 
 
Results 
 
Heart specific expression of CAR rescues the embryonic lethal CAR KO 
phenotype. 
CAR is essential for embryonic development as knockouts die in mid-gestation with cardiac 
malformations and hemorrhage (32–34). To test if survival exclusively depends on CAR expression in the 
heart and to potentially circumvent the embryonic lethal KO phenotype, we used a genetic rescue 
approach with cardiac specific expression of chCAR in the CAR KO mouse. We inserted the coding 
region of chicken CAR into the MLC-2 expression vector and validated the construct by restriction 
analysis and sequencing of the open reading frame (Figure 1A). The MLC-2 promoter restricts expression 
to the heart and its perinatal regulation matches that of CAR with high expression in the embryo and 
reduced levels after birth (49). To confirm protein expression, the rat cardiomyoblast cell-line H9C2 was 
transfected with the MLC-2 chCAR expression construct followed by immunofluorescence staining with 
an anti-chCAR antibody (Figure 1B). After validation of protein expression and proper localization of 
chCAR at the plasma membrane, we used pronuclear microinjection of the linearized construct to obtain 
transgenic animals (TG). Founders with high expression levels of the chCAR transgene died within the 
first weeks of age (data not shown). Surviving transgenic animals were backcrossed to the CAR KO for 
two generations to obtain non-cardiac CAR KO animals (ncKO), which survive and do not display an 
obvious phenotype (Figure 1C, D). To validate the ncKO model we determined CAR protein expression 
by Western blot (Figure 1E) and CAR mRNA levels by qRT-PCR with specific primers discriminating 
mouse and chicken CAR. RNA from several tissues was isolated from 10-week-old mice, which express 
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CAR at low levels, but clearly distinct from the background signal in ncKO animals (Figure 1F). 
Expression of the transgenic chCAR was restricted to the heart of the ncKO mice (Figure 1G) with no 
activity of the MLC-2 promoter in other tissues. The transgenic animals as well as the ncKO mice 
developed normally. Their weight and the body composition of fat, free water, and muscle tissue did not 
differ from WT animals (Table 1). Because of the importance of CAR in cardiac development and 
function, the hearts of the ncKO mice and the parental transgenic strain underwent additional analysis. 
The heart weight to body weight ratio of these animals was normal (Figure 1H), as was the histology of 
adult hearts (Figure 1I). There were no signs of hypertrophy, dilation, or changes in tissue composition. 
The ultrastructure as determined by electron microscopy was unremarkable in the rescue animals, in 
contrast to the conventional (34) or cardiac (35) CAR KO. The myofilament structure, mitochondria, and 
intercalated discs appeared normal in all genotypes (Figure 1J). Cardiac function, as determined by 
echocardiography, was unchanged in TG or ncKO animals (Table 2). The electrical activity of the heart 
that was affected in the cardiac CAR KO with AV-block (35–37) was normal in both strains (Table 3). 
Thus, chCAR completely restores the cardiac function of mCAR in the rescue animals. Furthermore there 
were no obvious phenotypes observed caused by the deletion of CAR in other tissues studied, as the 
animals develop normally, have a normal body composition and an intact blood brain barrier (Figure 1K-
M). 
The CAR ncKO mouse is protected from CVB3 infection. 
The relevance of CAR and its co-receptors for virus entry and CVB3 associated pathology has recently 
been addressed using loss of function mutants in heart and pancreas (3, 4). To facilitate the differential 
analysis of multiple organs, and determine how CAR influences virus spread within the organism, we 
infected WT and ncKO animals intraperitoneally with the CVB3 Nancy strain. Ten days after infection 
tissues were isolated and analyzed for virus and associated pathology, such as signs of inflammation. Of 
the non-cardiac tissues analyzed, we found necrotic lesions in histological sections of the pancreas of WT 
but not ncKO animals (Figure 2A). The area of necrosis and inflammation with infiltration of 
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mononuclear cells was used to assign an arbitrary score from 0 (no damage) to 5 (30-100% affected area). 
For WT pancreas the inflammation score was 4.70±0.48 (mean±SD). Spleen, liver, kidney and lung 
appeared normal in both genotypes (score 0). In situ hybridization with a probe specific for viral plus-
strand RNA confirmed replicating virus in the exocrine pancreas of WT but not of ncKO animals (Figure 
2B). The presence of presence of viral RNA was scored from 0 (no positive cells) to 5 (30-100% positive 
cells). In the pancreas of wildtype mice the infection score was 4.20±0.42 (mean±SD). There was no viral 
RNA as a sign of replicating virus in ncKO animals (score 0). 
In a more global approach to virus infection we analyzed the immune response in animals exposed to 
CVB3. Intraperitoneal infection of ncKO mice did not result in the induction of inflammation markers. 
CVB3-specific IgG levels were increased from 4 through 10 days post infection (dpi) in wildtype animals, 
while ncKO animals did not produce a specific immune response. In the serum of ncKO mice 4 or 10 dpi 
there was no induction of the inflammation marker “regulated on activation, normal T-cell expressed and 
secreted” (RANTES). In contrast, WT animals had high levels of serum RANTES in the acute phase of 
the infection at 4 dpi, which decreased but was still elevated in the sub-acute phase at 10 dpi (Figure 3). 
As there was no prominent immune response to virus load in the ncKO mouse, we investigated if CVB3 
infection was blocked not only in non-cardiac cells, but also in cardiomyocytes of the rescue animals. We 
analyzed hearts from ncKO mice in the acute phase of infection and found that hearts expressing chCAR 
instead of mCAR were protected from CVB3 infection. Comparing WT vs. ncKO hearts at 4 and 10 dpi 
we found signs of infiltration, viral CVB3 RNA, and VP1 protein only in the wildtype but not in ncKO 
mice (Figure 4A-D). Quantification was based on the affected area and/or number of positive cells with 
infiltration based on histology (WT 1.30±0.48 vs. ncKO 0.0±0.0), in situ hybridization (WT 1.20±0.42 vs. 
ncKO: 0.0±0.0) and presence of capsid protein VP1 (WT 0.8±0.42 vs. ncKO: 0.0±0.0). 
We also tested the expression of the cytokine RANTES, Tumor Necrosis Factor alpha (TNFα), Interferon 
beta 1 (IFNβ1), Interleukin 6 (IL6), und Interleukin 10 (IL10) in infected heart tissue samples. In contrast 
to WT animals there was no induction in ncKO mice (Figure 4E). 
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To determine if the route of delivery in the ncKO mouse affected virus induced cardiac pathology, we 
performed a second set of infections delivering the virus intravenously to ensure that the virus reaches the 
heart. Viral RNA was present in wildtype hearts (infection score 1.25±0.50) and pancreas (infection score 
4.25±0.50). Again there were no histological signs of infection and no viral RNA in the hearts of infected 
ncKO animals (Figure 5A). Intravenous delivery resulted in a slight induction of CVB3 specific IgGs, but 
there was still a significant difference to WT animals with replicating virus (Figure 5B). The slight 
induction in the ncKO mouse might be caused by circulating virus in the blood and does not necessarily 
indicate a viral infection. Serum levels of RANTES were induced only in WT animals (Figure 5C). Taken 
together the protection from virus infection of non-cardiac and cardiac tissue when mouse CAR is 
replaced by chicken CAR indicates an important role for CAR in mediating virus uptake throughout the 
body and suggests a species-specific interaction of CVB3 with its receptor. 
 
CVB3 infection is species dependent. 
As chCAR restored the physiological functions of mCAR, but did not mediate CVB3 infection, we 
investigated differences in virus uptake in a cell culture system. Native CHO cells are not infected with 
the CVB3 Nancy strain but with the PD strain, which enters cells independently of CAR (50) and resulted 
in high virus titer (Figure 6A).  CHO cells, which do not express CAR and thus cannot be infected by the 
CVB3 Nancy strain (51), were transfected with mouse (m) or chicken (ch) CAR and subsequently infected 
with CVB3. Transfection of CHO cells with mouse CAR resulted in high levels of infection and virus 
replication verified by a plaque assay. Non-transfected CHO cells and cells transfected with chicken CAR 
were not infected (Figure 6B). To validate these findings, RNA from transfected cells 4 h post infection 
was isolated and analyzed by qRT-PCR. Viral RNA was only detected in cells expressing mCAR and not 
in cells expressing chicken or no CAR (Figure 6C). Non-transfected CHO cells were CAR negative, and 
only the transfected CAR species was expressed in the cells (Figure 6D, E). 
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To relate these functional differences to differences in the amino acid (AA) composition of chicken versus 
mouse CAR, we performed sequence alignments and modeled the interaction site of chicken CAR. As the 
N-terminal Ig-domain is most important for virus binding as well as the interaction with other IgSF 
proteins, and as the structures had been solved for human and mouse, we focused our analysis on that 
region (Figure 7). The published binding sites of CVB3 to CAR (15) comprise 27 AA of which 24 are 
identical between mouse and human (89% homology). The differentiating AAs are located close to the D2 
domain of CAR suggesting only minor relevance of this region for virus binding. In contrast the homology 
of CVB3 binding AAs between mouse and chicken is 63% (17 identical AAs). Modeling of the chicken 
CAR D1 domain locates changed AAs also to the upper part of the D1 domain. The published interaction 
sites between two CAR molecules (25, 26) are highly conserved between mouse and human (100%) and 
mouse and chicken (80%). The differential AAs are not clustered but distributed throughout the D1 
domain. These species-specific differences might explain why chCAR can render the cellular function of 
CAR but not CVB3 replication. 
With the generation of our novel ncKO mouse we were able to show that the essential function of CAR in 
vivo is related to cardiac development. The species-specific differences in virus uptake versus cardiac 
function became apparent as chCAR restored normal heart development but did not mediate virus 
infection. This can be explained by differential conservation of virus binding sites versus sites involved in 
cellular interactions. 
 
Discussion 
 
CAR is a multifunctional protein that not only mediates uptake of coxsackieviruses type B and 
adenoviruses, but that is also required for critical cellular functions such as cell contact formation and 
signal transduction. Thus, CAR deficient mice die early in embryonic development (32–34). In this study 
we show, that the expression of chicken CAR in the mouse heart is sufficient to rescue the embryonic 
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lethal CAR KO phenotype as it adopts the physiological functions of mouse CAR. Surprisingly, it does 
not restore susceptibility to coxsackievirus infection. 
To study the cellular function of CAR various KO mice have been generated. The conventional KO of 
CAR exon 1 or 2 leads to cardiac malformations and embryonic lethality between day E11.5 and E13.5. 
Survival of cardiac specific knockout mice depends on the promoter driving the Cre transgene and the 
targeted exon ranging from complete lethality in the MHCcre driven KO of CAR exon 1 or the TnTcre 
driven KO of CAR exon 2 (33, 36) to survival of 20% or 100% of the embryos in the MHCcre driven 
CAR exon 2 KO (32–34). The inducible KO of CAR in the adult heart is compatible with life but results 
in an electrical phenotype with impaired cardiac function (35–37). Together these mouse models indicate 
an important role of CAR in development and function of the heart. 
Here we used a rescue approach to evaluate the role of CAR in extracardiac tissues and study species 
specific differences in virus uptake vs. cardiac physiology. We used the MLC-2 promoter, which mimics 
the physiological timing of CAR expression (49, 52, 53, 32) to expressed chicken CAR exclusively in the 
mouse heart. This approach was associated with a dose dependent lethality, as mice expressing high levels 
of the transgene died within the first weeks after birth while founders with lower chicken CAR expression 
survived. This is consistent with reported observations after a 6 fold overexpression of CAR in the 
heart (54). These animals develop cardiomyopathy and cardiac hypertrophy and die within their first 
month of life. In contrast, our surviving transgenic mice with low expression of the chCAR transgene and 
proper developmental regulation through the MLC-2 promoter do not show any obvious abnormalities. 
The chCAR transgene rescued the embryonic lethality of the homozygous CAR KO mice resulting in 
normal cardiac function and development of the ncKO animals (32–34). Thus, expression of CAR 
exclusively in the heart is sufficient for the survival of CAR KO embryos. 
Postnatal development of the ncKO mice was normal, including body weight, body composition, heart 
weight, and cardiac morphology. The spectrum of cardiac pathology in CAR KO mice ranges from 
enlarged mitochondria over thin myofilament bundles (34) to disrupted connections of the myofilaments 
to the intercalated discs (35). In contrast, there were no obvious morphological, ultrastructural, or 
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functional changes in our ncKO animals, including mechanics and electrical activity as determined by 
echocardiography and ECG. The electrical conduction defect with severe AV-block – the hallmark of the 
adult CAR knockout heart (35, 36), was completely restored with the chicken transgene. Indeed, normal 
cardiac development and function in the ncKO mouse indicates that chCAR can replace the physiological 
function of the endogenous CAR in the mouse heart. 
The survival of the ncKO mouse suggests that CAR is not a critical component in the development of 
extracardiac tissues. The phenotype of the tamoxifen inducible ubiquitous CAR knockout (55) with 
tamoxifen injection at E12.5 resulted in death on day E18.5. The embryos suffered from subcutaneous 
edema and hemorrhages and the presence of erythrocytes in lymphatic vessels had been attributed to a 
potential contribution of CAR to the separation between blood and lymphatic vessels (55). Our analysis of 
the ncKO mouse, which did not reproduce this phenotype, would suggest that the hemorrhage is more 
likely secondary to the cardiac phenotype and not a vascular defect. 
The expression of CAR in male germ cells and sertoli cells suggests a function for CAR in male fertility 
(56, 57). As our animals breed and produce normal litters, an essential function in male fertility can be 
excluded. These findings are consistent with the inducible ubiquitous down-regulation of CAR in adult 
mice that has no effect on metabolism, fertility or behavior (37). The localization of CAR to tight 
junctions implies a role for CAR in epithelial barrier function and tissue homeostasis (58). Accordingly, 
we investigated the blood-brain-barrier in ncKO mice and did not find an increased permeability 
indicating an intact barrier function. The lack of an obvious extracardiac phenotype in the ncKO mouse 
under baseline conditions does not exclude a role for CAR in non-cardiac tissues and we anticipate that 
future appropriate challenges will help develop the ncCAR-KO as a suitable tool to study the role of CAR 
in the lung endothelium, kidney or in the migration of neutrophils (59). Conveniently, the robust rescue 
avoids the necessity to induce the CAR deficiency and provides a complete loss of CAR in all cells from 
early embryonic development. 
Challenging wildtype mice with CVB3 resulted in infection, virus replication, and the expected pathology, 
predominantly in heart and pancreas as the prime target tissues (3, 4). The ncKO mouse was protected 
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from virus-induced pathology. Unexpectedly, this did not only involve non-cardiac tissues but also the 
heart, which did not show any signs of infections despite the cardiac expression of chCAR. In hearts of 
infected rescue animals we did not detect viral RNA by in situ hybridization or TaqMan analysis or CVB3 
capsid protein VP1. There were no signs of histopathology and no induction of an immune response in 
infected ncKO animals. A similar protection of the pancreas or heart has been reported in the respective 
tissue-specific CAR KO mice with reduced virus load, inflammation, and tissue damage compared to WT 
mice (3, 4). The absence of viral replication in heart or pancreas as primary organs of CVB3 replication 
was not associated with reduced virus spread or replication in other organs (3, 4). 
To exclude a compartmentalization effect where the loss of CAR in non-cardiac tissue prevents virus 
spread, we monitored cardiac infection after intravenous versus intraperitoneal delivery of CVB3. Neither 
route of virus administration resulted in cardiac damage or viral replication. After intravenous application 
we detected CVB3 specific antibodies in the serum of infected rescue animals, although at lower levels 
than wildtypes. The production of antibodies likely results from circulating virus in the blood and not from 
the infection, as the induction of an immune response by non-replicating virus capsids has previously been 
described (60). 
With mounting evidence that chCAR does not mediate virus entry in vivo, we used a cell culture based 
system to eliminate the complicating effects of virus spread and immune response. In CAR negative CHO 
cells transfected with mouse or chicken CAR we compared virus replication via plaque assays and found 
that unlike mouse CAR, chCAR does not mediate CVB3 infection. CVB3 has been reported to infect 
several species, including humans and other primates (5–7), mice, and dogs (8, 9). Infections of non-
mammalian species have not been reported, but transfection of CAR negative CHO cells with zebrafish 
CAR enables CVB3 infection (61). Chicken CAR did not mediate virus uptake into CHO cells, possibly 
related to the diverse amino acid sequences with homology between zebrafish and chicken CAR of only 
51%. While amino acid conservation of CAR is high between mammals, there is a considerable disparity 
to non-mammalian species, specifically between sites involved in cellular vs. virus/host interactions. 
Specifically the CVB3 binding sites are highly conserved between human and mouse but not between 
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human and chicken. Modeling of the protein structure locates the 10 non-conserved AAs between human 
and chicken throughout the D1 region. In contrast, the three AAs differentiating human and mouse locate 
in D1 close to the D2 domain that is not as accessible for interactions as the distal region of the molecule. 
Amino acids of the N-terminal Ig domain that are involved in the physiological interaction between CAR 
molecules or CAR and other members of the IgSF and the cytoplasmic tail with its PDZ consensus site 
(GSIV) are conserved between human, mouse and chicken (15). This suggests that amino acids involved 
in CAR’s physiological interactions underlie a higher selection pressure and are conserved between 
species versus amino acids that relate to the interaction with pathogens. Thus, CAR dependent cell-
contacts and signaling pathways can be sustained by chCAR but not CVB3 infection. 
In summary, expression of chCAR in the heart of CAR knockout mice has allowed us to rescue the 
embryonic lethal KO phenotype and address interspecies differences in virus-host interactions. Replacing 
mouse with chicken CAR protects from CVB3 infection but maintains normal cardiomyocyte morphology 
and function. Thus, the cardiac rescue survives and does not display any obvious non-cardiac phenotypes. 
Accordingly, we expect only minor non-muscle side effects from CAR directed therapeutic strategies and 
added safety for cardiac antiviral strategies that exploit species specific differences in CAR physiology vs. 
pathology. 
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Figure Legends: 
 
Fig. 1. Generation and basic characterization of the non-cardiac CAR knockout mouse (ncKO). 
(A) The CAR expression construct contains the MLC-2 promoter, β-globin intron 2, chicken CAR cDNA 
(chCAR) and the SV40 polyadenylation sequence (SV40pA). (B) Proper expression and localization was 
validated by immunofluorescense of chCAR (green) in H9C2 cells. Nuclei are stained in blue (DAPI). 
Size bar 20 µm. (C) Breeding scheme: The MLC promoter drives expression of chCAR exclusively in the 
heart (a). Mouse CAR is expressed from the wildtype alleles. The heterozygous knockout contains a 
recombined CAR allele with a residual lox side after excision of Exon 1 (triangle, b). Homozygous CAR 
knockout mice with the chCAR transgene (k) are available after two generations. (D) Pedigree of the heart 
specific CAR rescue animals with the parental (P), F1, and F2 generations. Genotypes of animals (a-k) are 
provided below. The transgenic mouse expresses chicken CAR (chCAR) under control of the heart 
specific MLC-2 promoter (a). These animals were mated with heterozygote CAR deficient mice carrying 
the recombined mouse CAR allele (CAR rec, b). Heterozygous offspring with (e) and without transgene 
(f) were mated to obtain the non-cardiac CAR KO animals (k). (E) In transgenic animals, chicken CAR 
(chCAR) protein is expressed and localizes to the intercalated disc. (F) In wildtype tissues, Mouse CAR 
mRNA is expressed at normal levels as determined by TaqMan analysis, while expression in non-cardiac 
knockout mice (ncKO) is at the detection limit (Fc = fold change). (G) The chCAR transgene is 
exclusively expressed in the hearts of ncKO animals. (H) Heart weight to bodyweight ratio (HW/BW) was 
normal in transgenic and ncKO animals. (I) Masson`s Trichrome staining of paraffin sections from hearts 
of 10 weeks old wildtype (WT), chCAR transgenic (TG), and non-cardiac CAR KO (ncKO) mice. There 
were no differences in heart morphology and tissue composition. Size bar 1 mm. (J) Ultrathin sections of 
hearts from 10 weeks old WT, transgenic and ncKO mice were analyzed by electron microscopy. The left 
panel panel shows the intercalated discs, the right panel the myofilament structure with mitochondria. 
There were no differences in cardiac ultrastructure. Size bar 2 µm. (K) CAR WT and ncKO mice were 
injected intravenously with 2% Evans Blue (EB) dye to test the blood-brain barrier function. The brains 
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(J) of both WT and ncKO mice showed no signs of dye leakage, as opposed to WT and ncKO kidneys (L) 
that stained dark blue. (M) Absorbance measurement of extravagated EB confirmed that ncKO mice had 
no increase of the dye content in the brain compared to WT. The amount of EB extracted from the brains 
of both WT and ncKO animals was significantly lower than the amount extracted from the kidneys (P < 
0.001). WT: n = 4, ncKO: n = 4. Size bar 1 cm 
 
Fig. 2. In ncKO mice, non- cardiac tissues are protected from CVB3 infection. 
CAR WT and ncKO animals were inoculated intraperitoneally with 1x105 pfu CVB3 Nancy strain and 
analyzed after 10 days by H&E staining and in situ hybridization on paraffin sections. (A) H&E staining 
reveals necrosis and inflammation with infiltration of mononuclear cells in WT pancreas, which is not 
detected in the ncKO animals. The morphology of spleen, liver, kidney, and lung was normal. There was 
no sign of infection in any ncKO tissue analyzed. (B) CVB3 infection was documented by the presence of 
viral RNA in WT pancreas. There was no viral RNA as a sign of replicating virus in ncKO animals. WT, 
n = 10; ncKO, n = 10; Size bar, 50 µm. 
 
Fig. 3. The immune response to CVB3 is not induced in ncKO mice. 
Serum of CVB3 inoculated WT and ncKO animals was collected 4 and 10 days after infection (dpi, days 
post infection). (A) Specific antibody production was determined using a CVB3 serum ELISA. 4 dpi 
CVB3-specific IgGs are present in WT animals and raise through day 10 days post infection. No CVB3 
specific antibodies were detected in ncKO animals. (B) In the acute phase of infection the inflammation 
marker RANTES was up-regulated more than 5-fold in the serum of WT, but not of ncKO animals. 10 dpi 
serum levels of RANTES are decreased in WT mice but still elevated as compared to ncKO mice. *, P < 
0.05; ***, P<0.005. uninfected: WT n = 3, ncKO n = 6; 4 dpi: WT n = 4, ncKO n = 3; 10dpi: WT n = 6, 
ncKO n = 8. 
 
Fig. 4. Replacing mouse with chicken CAR prevents CVB3 entry and the associated cardiac pathology. 
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Analysis of virus uptake and the associated immune response in hearts expressing mouse vs. chicken CAR 
(CAR WT and ncKO animals). (A) H&E staining documents the infiltration with mononuclear cells and 
(B) replicating virus detected by in situ hybridization of wildtype but not ncKO hearts10 days after 
intraperitoneal infection with CVB3. Viral RNA detected by (C) quantitative RT-PCR as well as (D) the 
viral capsid protein VP1 was only present in the hearts of WT but not ncKO mice 4 dpi infection. (E) The 
inflammation markers RANTES, TNFα, IFNβ1, IL6, and IL10 were induced only in the hearts of WT but 
not in ncKO animals as determined by TaqMan analysis. *, P < 0.05; **, P < 0.01; P < 0.001. WT: n = 4, 
ncKO n = 3. Size bar 50 µm. 
 
Fig. 5. Protection from CVB3-associated pathology is independent from the delivery route. 
CAR WT and ncKO animals were inoculated intravenously with 1x106 pfu CVB3 Nancy strain. (A) 10 
dpi viral RNA was present in heart and pancreas of WT, but not ncKO animals as detected by in situ 
hybridization of paraffin sections. (B) CVB3 specific antibodies were detected in both, WT and ncKO 
animals using a coxsackievirus IgG specific ELISA. The immune response was significantly reduced in 
ncKO animals. (C) Serum level of RANTES at 10 dpi were increased only in WT animals. * P < 0.05; 
***, P < 0.001; WT: n = 4, ncKO n = 5. Size bar 50 µm. 
 
Fig. 6. Species specific variation in CAR affects CVB3 infection. 
CAR negative CHO cells were transfected with CAR from mouse (mCAR), and chicken (chCAR), 
infected with CVB3 and analyzed using a plaque assay. (A) The CVB3 Nancy strain does not replicate in 
CAR negative CHO cells whereas the CVB3 PD strain infects cells independent of CAR. (B) Replicating 
virus only arose from cells transfected with mCAR. Untransfected CHO cells or cells transfected with 
chCAR did not contain virus. (C) 4 h post infection, CVB3 RNA was only present in mCAR transfected 
cells and not in those expressing chCAR. (D, E) Taqman analysis confirmed the species-specific CAR 
expression. 
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Fig. 7. Cellular and viral CAR binding sites differ between species. 
Sequence analysis and modeling of the N-terminal Ig-domain of human, mouse, and chicken CAR. 
Published binding sites of the CAR-CVB3 interaction or CAR-CAR are displayed on a dark grey 
background. Homology to the published sites are indicated by the light grey background. (A) Alignment 
of the first D1 domain shows the conservation of AA within the binding sites for CVB3 between H. 
sapiens, M. musculus, and G. gallus. Three AA are exchanged between human and mouse, 7 additional 
AAs in chicken (indicated in red). An asterisk indicates a position with a single, fully conserved residue. 
A colon indicates conservation between groups of strongly similar properties. A period indicates 
conservation between groups of weakly similar properties. (B) The structure of the human and mouse Ig-
domains have been solved and the G. gallus D1 domain was modeled by using human D1 domain as a 
template. Non-conserved AAs are indicated in red. The additional AA exchanges in G. gallus mainly 
affect the upper part of the molecule. (C) The AA involved in CAR dimerization (blue) are well conserved 
between species with complete identity between mouse and human and 4 additional mutations in chicken. 
(D) The mutations affecting AAs in the chicken Ig-domain (red) do not cluster within the structure. 
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Tables 
TABLE 1: Body composition analysis of transgenic and ncKO animals 
 WT (n = 6) TG (n = 6) ncKO (n = 6) 
weight [g] 23.00 ± 4.22  24.07 ± 4.79 20.93 ± 4.72 
fat [%] 15.19 ± 1.08 14.43 ± 1.01 16.95 ± 3.41 
free water [%] 6.43 ± 0.42 6.75 ± 0.74 6.67 ± 0.56 
muscle [%] 75.96 ± 1.18 76.51 ± 1.46 74.16 ± 3.97 
 
  
TABLE 2: Echocardiography of transgenic and ncKO animals 
 WT (n = 8) TG (n = 5) ncKO (n = 6) 
BW [g]  21.84 ± 3.05  25.14 ± 3.84  20.92 ± 4.64 
HW [mg]  99.16 ± 11.06  116.17 ± 23.94  106.45 ± 25.95 
HW/BW [mg/g]  4.57 ± 0.41  4.63 ± 0.50  5.15 ± 1.01 
LVD diastole [mm]  4.16 ± 0.18  4.13 ± 0.52  3.99 ± 0.45 
LVD systole [mm]  3.09 ± 0.23  3.06 ± 0.29  2.99 ± 0.41 
FS [%]  25.64 ± 4.46  26.24 ± 2.32  25.12 ± 4.57 
EF [%]  50.92 ± 7.61  51.12 ± 4.71  48.96 ± 6.71 
BW: body weight, HW: heart weight, LVD: left ventricular diameter,  
FS: fractional shortening, EF: ejection fraction 
 
  
TABLE 3: ECG of transgenic and ncKO animals 
 WT (n = 6) TG (n = 6) ncKO (n = 6) 
PR Interval [ms]  39.70 ± 1.14  41.22 ± 1.36  39.49 ± 3.08 
QRS Interval [ms]  13.26 ± 1.55  11.74 ± 1.65  11.32 ± 1.45 
QT Interval [ms]  25.66 ± 1.79  26.05 ± 2.14  25.70 ± 0.91 
P Amplitude [mV]  0.08 ± 0.02  0.09 ± 0.02  0.11 ± 0.02 
Q Amplitude [mV]  ‐0.05 ± 0.03  ‐0.06 ± 0.04  ‐0.08 ± 0.08 
R Amplitude [mV]  1.55 ± 0.34  1.53 ± 0.35  1.60 ± 0.37 
S Amplitude [mV]  ‐0.45 ± 0.15  ‐0.33 ± 0.27  ‐0.49 ± 0.26 
 
